M
Marco Losa
Researcher at Vita-Salute San Raffaele University
Publications - 255
Citations - 10428
Marco Losa is an academic researcher from Vita-Salute San Raffaele University. The author has contributed to research in topics: Pituitary adenoma & Adenoma. The author has an hindex of 52, co-authored 236 publications receiving 8938 citations. Previous affiliations of Marco Losa include University of Brescia & University of Milan.
Papers
More filters
Journal ArticleDOI
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
Francesco Perrone,Andrea Lampis,Marta Orsenigo,M. Di Bartolomeo,Arpine Gevorgyan,Marco Losa,Milo Frattini,C Riva,Salvatore Andreola,Emilio Bajetta,Lucio Bertario,Ermanno Leo,Marco A. Pierotti,Silvana Pilotti +13 more
TL;DR: Patients carrying KRAS mutations or with activated PI3K profiles can benefit from targeted treatments only by switching off molecules belonging to the downstream signalling of activated EGFR, such as mammalian target of rapamycin.
Journal ArticleDOI
Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group.
TL;DR: It is demonstrated that transsphenoidal surgery is a safe and effective treatment for patients with Cushing's disease, however, after successful surgery there is a steady increase in the percentage of recurrences, which continues with time.
Journal ArticleDOI
Results of transsphenoidal surgery in a large series of patients with pituitary adenoma.
TL;DR: Transsphenoidal surgery is an effective and safe treatment for most patients with pituitary adenoma and could be considered the first-choice therapy in all cases except for prolactinomas responsive to dopamine agonists.
Journal ArticleDOI
Non-functioning pituitary adenoma database : a useful resource to improve the clinical management of pituitary tumors
Emanuele Ferrante,Monica Ferraroni,Tristana Castrignanò,Laura Menicatti,Mascia Anagni,Giuseppe Reimondo,Patrizia Del Monte,Donatella Bernasconi,Paola Loli,Marco Faustini-Fustini,Giorgio Borretta,Massimo Terzolo,Marco Losa,Alberto Morabito,Anna Spada,Paolo Beck-Peccoz,Andrea Lania +16 more
TL;DR: The database indicates that the goal of a definitive surgical cure has been achieved during the last decade in a low percentage of patients with NFPA, and may help to reduce the delay between symptom onset and diagnosis.
Journal ArticleDOI
IL-23 secreted by myeloid cells drives castration-resistant prostate cancer
Arianna Calcinotto,Clarissa Spataro,Elena Zagato,Diletta Di Mitri,Veronica Gil,Mateus Crespo,Gaston De Bernardis,Marco Losa,Michela Mirenda,Emiliano Pasquini,Andrea Rinaldi,Semini Sumanasuriya,Maryou B. Lambros,Antje Neeb,Roberta Lucianò,Carlo Andrea Bravi,Daniel Nava-Rodrigues,David Dolling,Tommaso Prayer-Galetti,Ana Ferreira,Alberto Briganti,Antonio Esposito,Simon T. Barry,Wei Yuan,Adam Sharp,Johann S. de Bono,Andrea Alimonti +26 more
TL;DR: Results reveal that MDSCs promote CRPC by acting in a non-cell autonomous manner and Treatments that block IL-23 can oppose MDSC-mediated resistance to castration in prostate cancer and synergize with standard therapies.